JPWO2020076853A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020076853A5 JPWO2020076853A5 JP2021519642A JP2021519642A JPWO2020076853A5 JP WO2020076853 A5 JPWO2020076853 A5 JP WO2020076853A5 JP 2021519642 A JP2021519642 A JP 2021519642A JP 2021519642 A JP2021519642 A JP 2021519642A JP WO2020076853 A5 JPWO2020076853 A5 JP WO2020076853A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- sequence
- acid sequence
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2018/055084 WO2019074973A2 (en) | 2017-10-10 | 2018-10-09 | ANTI-CD38 ANTIBODIES AND METHODS OF USE |
| USPCT/US2018/055084 | 2018-10-09 | ||
| US201962831608P | 2019-04-09 | 2019-04-09 | |
| US201962831572P | 2019-04-09 | 2019-04-09 | |
| US62/831,572 | 2019-04-09 | ||
| US62/831,608 | 2019-04-09 | ||
| EP19306097 | 2019-09-11 | ||
| EP19306097.7 | 2019-09-11 | ||
| PCT/US2019/055232 WO2020076853A1 (en) | 2018-10-09 | 2019-10-08 | Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512649A JP2022512649A (ja) | 2022-02-07 |
| JPWO2020076853A5 true JPWO2020076853A5 (enExample) | 2022-10-17 |
| JP7462621B2 JP7462621B2 (ja) | 2024-04-05 |
Family
ID=70165121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021519642A Active JP7462621B2 (ja) | 2018-10-09 | 2019-10-08 | 三重特異性抗ｃｄ３８、抗ｃｄ２８、および抗ｃｄ３結合タンパク質ならびにウイルス感染を処置するための使用方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11530268B2 (enExample) |
| EP (1) | EP3864043A1 (enExample) |
| JP (1) | JP7462621B2 (enExample) |
| KR (1) | KR20210075129A (enExample) |
| CN (1) | CN113166254A (enExample) |
| AU (1) | AU2019357467A1 (enExample) |
| BR (1) | BR112021006558A2 (enExample) |
| CA (1) | CA3115679A1 (enExample) |
| CO (1) | CO2021004534A2 (enExample) |
| IL (1) | IL282126A (enExample) |
| MX (1) | MX2021004147A (enExample) |
| SG (1) | SG11202103478RA (enExample) |
| TW (1) | TWI856979B (enExample) |
| WO (1) | WO2020076853A1 (enExample) |
| ZA (1) | ZA202102223B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI838039B (zh) * | 2011-03-28 | 2024-04-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| TN2018000324A1 (en) * | 2015-01-23 | 2020-01-16 | Sanofi Sa | ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123 |
| BR112018008011A2 (en) | 2015-10-25 | 2018-10-30 | Sanofi | trypecific and / or trivalent binding proteins for prevention or treatment of HIV infection |
| KR20240036142A (ko) | 2016-04-13 | 2024-03-19 | 사노피 | 3특이성 및/또는 3가 결합 단백질 |
| US10882922B2 (en) | 2016-04-13 | 2021-01-05 | Sanofi | Trispecific and/or trivalent binding proteins |
| SG11202003212PA (en) | 2017-10-10 | 2020-05-28 | Sanofi Sa | Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies |
| CN112585165B8 (zh) | 2018-04-25 | 2025-02-14 | 普罗米修斯生物科学公司 | 优化的抗tl1a抗体 |
| BR112021006558A2 (pt) | 2018-10-09 | 2021-07-13 | Sanofi | proteínas de ligação triespecíficas anti-cd38, anti-cd28 e anti-cd3 e métodos de uso para o tratamento de infecção viral |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| MX2021012386A (es) * | 2019-04-09 | 2022-01-18 | Sanofi Sa | Proteínas de union triespecíficas, métodos y usos de las mismas. |
| MX2022004942A (es) | 2019-10-24 | 2022-07-27 | Prometheus Biosciences Inc | Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos. |
| WO2022040482A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| CN116648459A (zh) * | 2020-10-12 | 2023-08-25 | 格雷菲克斯公司 | 靶向响应SARS-CoV蛋白表达细胞的T细胞的抗体构建体、其设计和用途 |
| JP2024503027A (ja) | 2021-01-11 | 2024-01-24 | サナ バイオテクノロジー，インコーポレイテッド | Ｃｄ８標的ウイルスベクターの使用方法 |
| HRP20250696T1 (hr) | 2021-01-28 | 2025-08-01 | Regeneron Pharmaceuticals, Inc. | Sastavi i postupci za liječenje sindroma oslobađanja citokina |
| EP4381081A1 (en) | 2021-08-04 | 2024-06-12 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
| EP4472646A1 (en) | 2022-02-01 | 2024-12-11 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| MX2024010339A (es) | 2022-02-23 | 2024-09-30 | Xencor Inc | Anticuerpos anti-cd28 x anti-psma. |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| AU2023254191A1 (en) | 2022-04-11 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| WO2023215560A1 (en) | 2022-05-05 | 2023-11-09 | Atoosa Corporation | Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp) |
| WO2023246911A1 (zh) * | 2022-06-24 | 2023-12-28 | 北京可瑞生物科技有限公司 | 基于t细胞受体的双特异性多肽分子及其用途 |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024173830A2 (en) | 2023-02-17 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025027003A1 (en) | 2023-07-31 | 2025-02-06 | Sanofi | Methods and uses for anti-cd38 t cell engagers in treatment of peripheral t-cell lymphomas |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2058199T3 (es) | 1987-09-23 | 1994-11-01 | Bristol Myers Squibb Co | Heteroconjugados de anticuerpos para la eliminacion de celulas infectadas por el vih. |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| PT1068241E (pt) | 1998-04-02 | 2007-11-19 | Genentech Inc | Variantes de anticorpos e respectivos fragmentos |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| CA2529945A1 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| CN100376599C (zh) | 2004-04-01 | 2008-03-26 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体 |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| NZ589434A (en) | 2008-06-03 | 2012-11-30 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| WO2011038290A2 (en) | 2009-09-25 | 2011-03-31 | The U. S. A., As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 and their use |
| EP2580243B1 (en) | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| TWI838039B (zh) | 2011-03-28 | 2024-04-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| WO2012154312A1 (en) | 2011-05-09 | 2012-11-15 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Neutralizing antibodies to hiv-1 and their use |
| US9783594B2 (en) | 2011-05-17 | 2017-10-10 | The Rockefeller University | Human immunodeficiency virus neutralizing antibodies and methods of use thereof |
| CN104080805B (zh) | 2011-11-07 | 2017-02-22 | 美国政府健康及人类服务部 | gp41中和性抗体及其用途 |
| CA2858716C (en) | 2011-12-08 | 2021-10-12 | Peter D. Kwong | Neutralizing antibodies to hiv-1 and their use |
| WO2013163427A1 (en) | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
| US9951106B2 (en) | 2012-12-04 | 2018-04-24 | University Of Maryland, Baltimore | Recombinant fusion protein comprising HIV gp120 linked to an enhancing CD4 binding site mAb |
| US20140213772A1 (en) | 2012-12-28 | 2014-07-31 | Abbvie, Inc. | Cross-over dual variable domain immunoglobulin constructs |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| WO2014116846A2 (en) | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| BR112015023557A2 (pt) | 2013-03-15 | 2017-10-24 | Abbvie Inc | proteínas de ligações dual específicas direcionadas contra tnfa |
| JP2016538275A (ja) | 2013-11-04 | 2016-12-08 | グレンマーク ファーマシューティカルズ， エセ．アー． | Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造 |
| MX385936B (es) | 2014-03-28 | 2025-03-11 | Xencor Inc | Anticuerpos biespecíficos que se unen a cd38 y cd3. |
| CN106687584B (zh) * | 2014-09-04 | 2021-08-13 | 干细胞技术公司 | 用于t细胞或nk细胞活化和扩增的可溶性抗体复合物 |
| EP3237449A2 (en) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Trispecific antibodies |
| TN2018000324A1 (en) | 2015-01-23 | 2020-01-16 | Sanofi Sa | ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123 |
| WO2016196740A1 (en) | 2015-06-02 | 2016-12-08 | The Rockefeller University | Tri-specific antibodies for hiv therapy |
| BR112018008011A2 (en) | 2015-10-25 | 2018-10-30 | Sanofi | trypecific and / or trivalent binding proteins for prevention or treatment of HIV infection |
| CN105837688B (zh) | 2015-11-20 | 2019-02-26 | 北京大学深圳研究生院 | 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞 |
| US10882922B2 (en) | 2016-04-13 | 2021-01-05 | Sanofi | Trispecific and/or trivalent binding proteins |
| WO2018120842A1 (zh) * | 2016-12-30 | 2018-07-05 | 上海欣百诺生物科技有限公司 | 一种双功能分子及其应用 |
| CN108264557B (zh) * | 2016-12-30 | 2021-08-24 | 惠和生物技术(上海)有限公司 | 一种结合cd3和t细胞负共刺激分子的双功能分子及其应用 |
| WO2018151841A1 (en) | 2017-02-17 | 2018-08-23 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
| SG11202003212PA (en) * | 2017-10-10 | 2020-05-28 | Sanofi Sa | Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies |
| BR112021006558A2 (pt) | 2018-10-09 | 2021-07-13 | Sanofi | proteínas de ligação triespecíficas anti-cd38, anti-cd28 e anti-cd3 e métodos de uso para o tratamento de infecção viral |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| MX2021012386A (es) * | 2019-04-09 | 2022-01-18 | Sanofi Sa | Proteínas de union triespecíficas, métodos y usos de las mismas. |
-
2019
- 2019-10-08 BR BR112021006558-0A patent/BR112021006558A2/pt not_active IP Right Cessation
- 2019-10-08 TW TW108136331A patent/TWI856979B/zh active
- 2019-10-08 CN CN201980079373.3A patent/CN113166254A/zh active Pending
- 2019-10-08 WO PCT/US2019/055232 patent/WO2020076853A1/en not_active Ceased
- 2019-10-08 CA CA3115679A patent/CA3115679A1/en active Pending
- 2019-10-08 US US16/596,474 patent/US11530268B2/en active Active
- 2019-10-08 AU AU2019357467A patent/AU2019357467A1/en active Pending
- 2019-10-08 JP JP2021519642A patent/JP7462621B2/ja active Active
- 2019-10-08 MX MX2021004147A patent/MX2021004147A/es unknown
- 2019-10-08 EP EP19791158.9A patent/EP3864043A1/en active Pending
- 2019-10-08 KR KR1020217013675A patent/KR20210075129A/ko not_active Ceased
- 2019-10-08 SG SG11202103478RA patent/SG11202103478RA/en unknown
-
2021
- 2021-04-01 ZA ZA2021/02223A patent/ZA202102223B/en unknown
- 2021-04-07 IL IL282126A patent/IL282126A/en unknown
- 2021-04-12 CO CONC2021/0004534A patent/CO2021004534A2/es unknown
-
2022
- 2022-11-11 US US18/054,734 patent/US20230357401A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020076853A5 (enExample) | ||
| JP2023085476A5 (enExample) | ||
| US20210309730A1 (en) | Multispecific antibodies | |
| IL258822B2 (en) | Trispecific and/or terrivalent binding proteins for the prevention or treatment of HIV infection | |
| JP2018537966A5 (enExample) | ||
| IL272747B2 (en) | Bispecific antibodies 1 + 2 | |
| JP2022512649A (ja) | 三重特異性抗ｃｄ３８、抗ｃｄ２８、および抗ｃｄ３結合タンパク質ならびにウイルス感染を処置するための使用方法 | |
| IL292780A (en) | A new 4-1bbl trimer containing antigen-binding molecules | |
| JP2019517539A5 (enExample) | ||
| GB2597851A (en) | Antibody molecules that bind to NKP30 and uses thereof | |
| RU2019123613A (ru) | Биспецифические антигенсвязывающие молекулы, содержащие антитело к4-1вв, клон 20н4.9 | |
| JP2019502712A5 (enExample) | ||
| JP2017537896A5 (enExample) | ||
| RU2015107891A (ru) | Антитела к asgpr и их применения | |
| JP2020529410A5 (enExample) | ||
| JP2017534646A5 (enExample) | ||
| CA3232364A1 (en) | Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof | |
| RU2017120360A (ru) | Биспецифические антитела и способы их применения в офтальмологии | |
| US20220144956A1 (en) | HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII | |
| JPWO2022087458A5 (enExample) | ||
| JPWO2022006380A5 (enExample) | ||
| RU2021112562A (ru) | Триспецифические связывающие белки, связывающие cd38, cd28 и cd3, а также способы применения для лечения вирусной инфекции | |
| US20250339519A1 (en) | Combination of cytokine fusion proteins with cd8 antigen binding molecules | |
| JPWO2023056252A5 (enExample) | ||
| IL318098A (en) | IGE-FCER pushers |